# Insulin Degludec (Tresiba)

> Ultra-long-acting basal insulin with >42-hour duration.

Source: https://peptides.cafe/peptide/insulin-degludec
Category: Insulin Analog · Endocrine
Tag: FDA-Approved · Diabetes

## Mechanism
Insulin analog with a hexadecanedioic acid side chain at LysB29 that forms soluble multi-hexamers at the injection site, releasing monomers slowly for flat, prolonged action.

## Research areas
- Basal insulin therapy
- Flexible dosing schedules
- Reduced nocturnal hypoglycemia

## Common research protocols
- Once-daily SC: Once-daily subcutaneous dose; timing flexibility within 8–40 hours between doses.

## Study summaries
- "DEVOTE trial" — NEJM (2017): Cardiovascular safety vs glargine with lower severe hypoglycemia.

## Considerations
- FDA-approved.
- Steady state reached after ~3 days.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.